What's New
-
Focus Areas
Our focus is on developing personalized cancer vaccines and designing next generation vaccines for infectious diseases.
-
Our Approach
In oncology, NEC Bio researchers lead the field by focusing on the identification of patient private –tumor specific neoantigens. In infectious diseases, our strategy is to target highly immunogenic antigens in regions of interest within pathogen genomes. These approaches drive our pioneering efforts in both fields.
-
AI
Our AI/ML suite is anchored by our core technologies: NEC Immune Profiler, NEC B-cell Epitope Predictor, as well as Digital Twin simulations.
-
Pipeline
Learn more about our pipeline currently in development at NEC Bio based on proprietary technologies that we have built in-house.
Partners
Target Indication: Ovarian cancer, head and neck cancer
Transgene and NEC are collaborating on the development of the TG4050 personalized cancer immunotherapy, which combines Transgene’s myvac® and NEC’s neoantigen prediction system. Two clinical trials are now underway.
NEC has made a Series A strategic investment in BostonGene, a pioneer in the use of biomedical software for advanced patient analysis. BostonGene has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno and targeted therapies.
Target Indication: Betacoronavirus
NEC is working with CEPI to develop vaccines that provide broad protection against SARS-CoV-2 and other betacoronaviruses.
Target Indications: Tropical diseases
NEC has entered into a research collaboration with Nagasaki University, for which it secured funding from SCARDA in September 2023.
SCARDA: Learn more
Nagasaki University: Learn more
Consortium
CONNECT is a landmark public-private consortium for the implementation of precision cancer medicine in Norway. The aim is to ensure infrastructure and collaboration on diagnostics, clinical trials, implementation of advanced precision medicine and use of health data for purposes including health economics analysis. By partnering with this consortium and leveraging advanced real-world data, NEC hopes to enhance and accelerate its development of personalized cancer immunotherapy.
